GSK, 14200 Shady Grove Road, Rockville, MD 20850, USA.
College of Veterinary Medicine, Qingdao Agricultural University, Qingdao 266109, China.
Mol Ther. 2019 Apr 10;27(4):757-772. doi: 10.1016/j.ymthe.2019.01.020. Epub 2019 Feb 7.
In the last two decades, there has been growing interest in mRNA-based technology for the development of prophylactic vaccines against infectious diseases. Technological advancements in RNA biology, chemistry, stability, and delivery systems have accelerated the development of fully synthetic mRNA vaccines. Potent, long-lasting, and safe immune responses observed in animal models, as well as encouraging data from early human clinical trials, make mRNA-based vaccination an attractive alternative to conventional vaccine approaches. Thanks to these data, together with the potential for generic, low-cost manufacturing processes and the completely synthetic nature, the prospects for mRNA vaccines are very promising. In addition, mRNA vaccines have the potential to streamline vaccine discovery and development, and facilitate a rapid response to emerging infectious diseases. In this review, we overview the unique attributes of mRNA vaccine approaches, review the data of mRNA vaccines against infectious diseases, discuss the current challenges, and highlight perspectives about the future of this promising technology.
在过去的二十年中,人们对基于 mRNA 的技术越来越感兴趣,希望将其用于开发针对传染病的预防性疫苗。RNA 生物学、化学、稳定性和输送系统方面的技术进步加速了全合成 mRNA 疫苗的发展。在动物模型中观察到的强大、持久和安全的免疫反应,以及早期人体临床试验的令人鼓舞的数据,使得基于 mRNA 的疫苗接种成为传统疫苗方法的一个有吸引力的替代方案。得益于这些数据,以及通用、低成本制造工艺的潜力和完全合成的性质,mRNA 疫苗的前景非常广阔。此外,mRNA 疫苗有可能简化疫苗的发现和开发,并促进对新出现的传染病的快速反应。在这篇综述中,我们概述了 mRNA 疫苗方法的独特属性,回顾了针对传染病的 mRNA 疫苗的数据,讨论了当前的挑战,并强调了这一有前途的技术的未来前景。